# CCR8-depleting antibodies restore response to radiotherapy plus anti-PD1 therapy in head and neck cancer by targeting intratumoral CCR8+ regulatory T cells

Source: [Biological sciences : nature.com subject feeds](https://www.nature.com/articles/s41467-026-79341-8) · 2026-11-13 · Life
Page: https://themorning.science/story/ccr8-depleting-antibodies-restore-response-to-radiotherapy-plus-anti-pd1-therapy-69e419e96cf73aed
Kind: research · Impact: medium

## In brief

- Research reports that CCR8-depleting antibodies restored response to radiotherapy plus anti-PD1 therapy in head and neck cancer.
- The approach targets intratumoral CCR8+ regulatory T cells.
- The source provided is a listing headline and title only, so further details are not available here.

## Why it matters

It suggests that depleting a specific regulatory T cell population within tumours may help restore response to a combination of radiotherapy and immunotherapy.

## Coverage

- [CCR8-depleting antibodies restore response to radiotherapy plus anti-PD1 therapy in head and neck cancer by targeting intratumoral CCR8+ regulatory T cells](https://www.nature.com/articles/s41467-026-79341-8) — Biological sciences : nature.com subject feeds, 2026-11-13

Tags: cancer, immunotherapy, radiotherapy, regulatory t cells, head and neck cancer

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science